Diabetes Fundamentals: Types, Diagnosis, Management, and Prevention
Diabetes Mellitus: A Comprehensive Overview
Diabetes is a group of metabolic disorders characterized by chronic hyperglycemia from defects in insulin secretion, insulin action, or both. It affects 38+ million Americans (11.6% of population); 1 in 5 undiagnosed.
Classification
| Type | Pathophysiology | Onset | Treatment Core |
|---|---|---|---|
| Type 1 (T1D) | Autoimmune β-cell destruction → absolute insulin deficiency | Usually <30 yrs (but any age) | Insulin (basal-bolus or pump) — lifesaving |
| Type 2 (T2D) | Insulin resistance + progressive β-cell failure → relative deficiency | Usually >40 yrs (increasing in youth) | Lifestyle + metformin ± other agents ± insulin |
| Gestational (GDM) | Placental hormones → insulin resistance in pregnancy | 24–28 wks gestation | Medical nutrition therapy ± insulin/metformin |
| Other specific types | MODY, LADA, pancreatic, drug-induced, genetic syndromes | Variable | Etiology-directed |
Diagnostic Criteria (ADA 2024)
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting plasma glucose | <100 mg/dL | 100–125 | ≥126 |
| HbA1c | <5.7% | 5.7–6.4% | ≥6.5% |
| 2-hr OGTT | <140 | 140–199 | ≥200 |
| Random PG + symptoms | — | — | ≥200 |
Confirm with repeat testing unless classic hyperglycemia crisis.
Classic Symptoms (Hyperglycemia)
- Polyuria, polydipsia, polyphagia
- Unexplained weight loss (esp. T1D)
- Fatigue, blurred vision
- Recurrent infections (UTI, candidiasis), slow healing
- Paresthesias (neuropathy)
Management Pillars
- Medical Nutrition Therapy: Individualized by RD; Mediterranean/DASH/plant-forward patterns; carb consistency/monitoring.
- Physical Activity: 150 min/week moderate aerobic + 2–3× resistance; reduce sedentary time.
- Pharmacotherapy: Metformin first-line T2D (unless contraindicated). Add agents per ASCVD/HF/CKD status, HbA1c, cost, preference (ADA/EASD algorithm).
- Glucose Monitoring: SMBG or CGM per regimen. T1D/insulin-using T2D → CGM standard.
- Cardiometabolic Risk Reduction: Statin, BP control (<130/80), SGLT2i/GLP-1 RA if ASCVD/HF/CKD, aspirin if indicated.
- Complication Screening: Annual dilated eye, UACR/eGFR, foot exam, lipid panel, dental.
Prevention (T2D Focus)
- DPP lifestyle intervention: 7% weight loss + 150 min/week → 58% risk reduction (71% if >60 yrs).
- Metformin for high-risk prediabetes (BMI ≥35, <60 yrs, GDM history).
Lifelong partnership: Diabetes requires a multidisciplinary team (PCP, endocrinologist, CDCES, RD, podiatrist, ophthalmologist, behavioral health) and an empowered patient. Regular follow-ups (q3–6 mo) adjust therapy to evolving life.
Diabetes - Related Articles
- Diabetic Shock: Recognizing Symptoms & Seeking Immediate Help
- Understanding Insurance Coverage for Type 1 Diabetes: Costs & Options
- Softclix Lancet Device: User Guide & Comfort Tips
- Type 1 Diabetes Incidence: Rising Rates, Peak Age, and Ethnic Patterns
- FreeStyle Flash Blood Glucose Meter: Features & Instructions
- Diabetes & Glaucoma: Understanding the Connection
- Understanding Diabetes Medication: Potential Side Effects & Management
